# Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence

> **NCT04404491** · PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital of Henan University of Science and Technology** · enrollment: 240 (estimated)

## Conditions studied

- Esophageal Malignant Neoplasm, Local Recurrence

## Interventions

- **DRUG:** Procedural death 1
- **DRUG:** Capecitabine
- **RADIATION:** Radiotherapy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04404491
- **Lead sponsor:** The First Affiliated Hospital of Henan University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2020-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04404491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04404491, "Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04404491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*